Results 51 to 60 of about 33,936 (220)

Induction of apoptosis in human colorectal cancer cells by nanovesicles from fingerroot (Boesenbergia rotunda (L.) Mansf.).

PLoS ONE, 2022
Colorectal cancer is the leading cause of cancer-related deaths worldwide, warranting the urgent need for a new treatment option. Plant-derived nanovesicles containing bioactive compounds represent new therapeutic avenues due to their unique ...
Saharut Wongkaewkhiaw, Amaraporn Wongrakpanich, Sucheewin Krobthong, Witchuda Saengsawang, Arthit Chairoungdua, Nittaya Boonmuen   +5 more
doaj   +1 more source

Promotion of colorectal cancer by transcription factor BHLHE40 involves upregulation of ADAM19 and KLF7

Frontiers in Oncology, 2023
BHLHE40 is a transcription factor, whose role in colorectal cancer has remained elusive. We demonstrate that the BHLHE40 gene is upregulated in colorectal tumors.
Yuan Sui, Hanlin Jiang, Collyn M. Kellogg, Sangphil Oh, Sangphil Oh, Ralf Janknecht, Ralf Janknecht, Ralf Janknecht   +7 more
doaj   +1 more source

Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles

, 2017
Cancer stem-like cells play a key role in tumor development, and these cells are relevant to the failure of conventional chemotherapy. To achieve favorable therapy for colorectal cancer, PEG-PCL-based nanoparticles, which possess good biological ...
Ning, Sin-Tzu;Lee, Shin-Yu;Wei, Ming-Feng;Peng, Cheng-Liang;Lin, Susan Yun-Fan;Tsai, Ming-Hsien;Lee, Pei-Chi;Shih, Ying-Hsia;Lin, Chun-Yen;Luo, Tsai-Yueh;Shieh, Ming-Jium, 謝銘鈞   +1 more
core   +1 more source

Long Non-Coding RNA CKMT2-AS1 Reduces the Viability of Colorectal Cancer Cells by Targeting AKT/mTOR Signaling Pathway

Iranian Journal of Public Health, 2022
Background: Colorectal cancer (CRC) has not only seriously affected people’s lives, but also burdened the government healthcare system. Long non-coding RNAs (lncRNA) have attracted more and more attention in the cancer study field.
Biao Zhuang, Xiong Ni, Zhijun Min, Dejun Wu, Tingfeng Wang, Peng Cui   +5 more
doaj  

Effect of RSK4 on biological characteristics of colorectal cancer

World Journal of Surgical Oncology, 2018
Background This study aimed to investigate the expression of P90 Ribosomal Protein S6 kinase 4 (RSK4) in colorectal cancer cells and its biological function.
Qingqing Ye, Xuan Wang, Min Jin, Meng Wang, Yan Hu, Shihu Yu, Yonghua Yang, Jiyuan Yang, Jun Cai   +8 more
doaj   +1 more source

Chemical Synthesis of the PAX Protein Inhibitor EG1 and Its Ability to Slow the Growth of Human Colorectal Carcinoma Cells

Frontiers in Oncology, 2021
Colorectal cancer is primarily a disease of the developed world. The incidence rate has continued to increase over time, reflecting both demographic and lifestyle changes, which have resulted in genomic and epigenomic modifications.
Lorissa McDougall, Jui Thiang Brian Kueh, Jake Ward, Joel D. A. Tyndall, Joel D. A. Tyndall, Adele G. Woolley, Adele G. Woolley, Adele G. Woolley, Sunali Mehta, Sunali Mehta, Sunali Mehta, Cherie Stayner, David S. Larsen, Michael R. Eccles, Michael R. Eccles, Michael R. Eccles   +15 more
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Discovery of highly potent and selective 7-ethyl-10-hydroxycamptothecin-glucose conjugates as potential anti-colorectal cancer agents

Frontiers in Pharmacology, 2022
7-Ethyl-10-hydroxycamptothecin (SN38), a highly potent metabolite of irinotecan, has an anticancer efficacy 100–1000 folds more than irinotecan in vitro. However, the clinical application of SN38 has been limited due to the very narrow therapeutic window
Chao Yang, Chao Yang, Chao Yang, An-Jie Xia, Cheng-Hao Du, Ming-Xing Hu, You-Ling Gong, Rong Tian, Xin Jiang, Yong-Mei Xie   +9 more
doaj   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source